With this study - Total Therapy IIIB - researchers are extending the findings of Total
Therapy III based what they have learned from the first two studies (Total Therapy I and II),
with new research strategies designed to explore why chromosome abnormalities found in
persons with multiple myeloma affect the outcome of drug therapy used in this disease."
It is well known that myeloma patients with chromosome abnormalities are at higher risk
because their disease tends to be more aggressive and does not respond to treatment as well
as patients without chromosome abnormalities. When researchers at the Myeloma Institute
looked at the results of Total Therapy II, they found that although research subjects with
chromosome abnormalities had better outcomes (how many responded, and how long they survived)
than those treated with standard chemotherapy; still their outcomes did not improve
significantly with Total Therapy II, when compared to Total Therapy I.
The research in this new study is designed to target this high-risk group of individuals with
chromosomal abnormalities. However, it is hoped that both groups of research participants -
those with and without chromosome abnormalities - will derive benefit from changes made in
this new research study.
- Patients must have newly diagnosed active MM requiring treatment. Patients with a
previous history of smoldering myeloma will be eligible if there is evidence of
progressive disease requiring chemotherapy.
- Protein criteria must be present (quantifiable serum M-component of IgG, IgA, IgD, or
IgE; urinary kappa or lambda light chain; or serum free light chain (SFLC) levels in
order to evaluate response. Non-secretory patients are eligible provided the patient
has > 20% plasmacytosis OR multiple (>3) focal plasmacytomas or focal lesions on MRI
OR diffuse hyperintense signal on STIR images in the absence of hematopoietic growth
- Patients must have received no more than one cycle or one month of prior chemotherapy
for this disease. Patients may have received prior radiotherapy provided approval has
been obtained by the Principal Investigator.
- Patients must be <75 years of age at the time of initial registration.
- Ejection fraction by ECHO or MUGA ≥ 40% performed within 60 days prior to
- Patients must have adequate pulmonary function studies > 50% of predicted on
mechanical aspects (FEV1, FVC, etc) and diffusion capacity (DLCO) > 50% of predicted,
within 60 days of registration. If the patient is unable to complete pulmonary
function tests due to MM related pain or condition, exception may be granted if the
principal investigator documents that the patient is a candidate for high dose
- Patients must have a performance status of 0-2 based on SWOG criteria. Patients with a
poor performance status (3-4), based solely on bone pain, will be eligible.
- All patients must be informed of the investigational nature of this study and must
have signed an IRB-approved informed consent in accordance with institutional and
- Platelet count < 30 x 109/L, unless myeloma-related.
- 18.104.22.168 Grade > 2 peripheral neuropathy.
- Hypersensitivity to bortezomib, boron, or mannitol.
- Uncontrolled diabetes.
- Recent (< 6 months) myocardial infarction, unstable angina, difficult to control
congestive heart failure, uncontrolled hypertension, or difficult to control cardiac
- Evidence of chronic obstructive or chronic restrictive pulmonary disease.
- Patients must not have light chain deposition disease or creatinine > 3 mg/dl
- Patients must not have prior malignancy, except for adequately treated basal cell or
squamous cell skin cancer, in situ cervical cancer, or other cancer for which the
patient has not received treatment for one year prior to enrollment. Other cancers
will only be acceptable if the patient's life expectancy exceeds five years.
- Patients must not have significant co-morbid medical conditions or uncontrolled life
- Pregnant or nursing women. Women of child-bearing potential must have a negative
pregnancy test documented within one week of registration. Women and men of
reproductive potential may not participate unless they have agreed to use an effective